Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 30 May, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Kilitch Drugs (India) Ltd

About the Company - Kilitch Drugs (India) Ltd

Kilitch Drugs(I) Ltd. is a Public Limited Listed company incorporated on 12/05/1992 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1992PLC066718 and registration number is 066718. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 105.16 Cr. and Equity Capital is Rs. 15.58 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsC-301/2, M.I.D.C., TTC Industrial Area, New Mumbai Maharashtra 400705info@kilitch.com
http://www.kilitch.com
Management
NamePosition Held
Mr. Mukund P MehtaManaging Director
Mr. Bhavin Mukund MehtaWhole Time Director
Mrs. Mira B MehtaWhole Time Director
Mr. Hemang J EngineerIndependent Director
Mr. Venkita Subramanian RajanIndependent Director
Prof. Vasudev Krishna MurtiIndependent Director

Basic Stock Data of Kilitch Drugs (India) Ltd

Last Updated: May 28, 2024, 9:58 pm

Market Cap 542 Cr.
Current Price 337
High / Low470/175
Stock P/E43.6
Book Value 104
Dividend Yield0.00 %
ROCE9.88 %
ROE5.40 %
Face Value 10.0
PEG Ratio0.57

Kilitch Drugs (India) Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales20.3319.9319.6223.5734.4336.6133.4530.7029.9745.4836.5641.2031.79
Expenses17.3119.6118.7119.9233.6631.5730.0326.7525.9939.2630.3832.5829.51
Operating Profit3.020.320.913.650.775.043.423.953.986.226.188.622.28
OPM %14.85%1.61%4.64%15.49%2.24%13.77%10.22%12.87%13.28%13.68%16.90%20.92%7.17%
Other Income0.371.511.050.171.310.380.970.240.691.020.560.492.96
Interest0.120.160.130.120.240.710.671.751.291.211.501.511.60
Depreciation0.500.500.440.700.201.130.820.890.930.910.710.820.81
Profit before tax2.771.171.393.001.643.582.901.552.455.124.536.782.83
Tax %21.30%40.17%47.48%14.00%62.80%36.03%40.00%-25.16%30.61%43.16%32.67%24.93%38.16%
Net Profit2.180.710.722.580.612.301.741.941.712.903.065.091.74
EPS in Rs1.430.460.761.390.721.861.341.561.522.282.162.951.81

Last Updated: May 7, 2024, 4:41 pm

Kilitch Drugs (India) Ltd Quarterly Chart

Kilitch Drugs (India) Ltd Profit & Loss

Last Updated: May 30, 2024, 2:57 am

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales14314610819212751825368114140155
Expenses1191249521252845755363104122132
Operating Profit232213-2-4-16705101823
OPM %16%15%12%-9%-19%-2%11%9%1%8%9%13%15%
Other Income00923213443335
Interest5430000111156
Depreciation665210102222243
Profit before tax131397-1-12-96925101219
Tax %22%20%22%70%4%5%16%55%48%27%35%31%
Net Profit101076-0-11-954146813
EPS in Rs7.757.9357.67-0.22-8.46-6.723.752.490.542.434.736.719.20
Dividend Payout %13%13%52%0%0%0%13%20%0%0%0%0%

Kilitch Drugs (India) Ltd Profit & Loss Yearly Chart

Kilitch Drugs (India) Ltd Growth

Compounded Sales Growth
10 Years:%
5 Years:22%
3 Years:38%
TTM:19%
Compounded Profit Growth
10 Years:%
5 Years:12%
3 Years:237%
TTM:62%
Stock Price CAGR
10 Years:31%
5 Years:12%
3 Years:26%
1 Year:59%
Return on Equity
10 Years:%
5 Years:3%
3 Years:4%
Last Year:5%

Last Updated: May 26, 2024, 12:56 am

Kilitch Drugs (India) Ltd Balance Sheet

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital13131313131314151515161616
Reserves6271101107958898106103112121131151
Borrowings43169001191315202229
Other Liabilities215354781115131261535141
Total Liabilities139153177127117113128144143203210220237
Fixed Assets444299423333323230656464
CWIP224300013203065343
Investments1013872495356535260716266
Other Assets726830462526353830477190104
Total Assets139153177127117113128144143203210220237

Kilitch Drugs (India) Ltd Reserves and Borrowings Chart

Kilitch Drugs (India) Ltd Cash Flow

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 1222-29-81711044663
Cash from Investing Activity -20-2441-31-20-2-4-14-10-38-158
Cash from Financing Activity 77-9-00-0617127-1
Net Cash Flow-162-39-2-023-510-210

Kilitch Drugs (India) Ltd Financial Efficiency Indicators

MonthMar 2010Mar 2011Mar 2012Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days123975124328619614886109122132142
Inventory Days46621212411084393670352810
Days Payable4437191241541841083389525239200
Cash Conversion Cycle1251214424324196798989-367-79-48
Working Capital Days10719-11419723712410079108-1442554
ROCE %15%8%-10%-9%5%6%1%3%6%10%

Kilitch Drugs (India) Ltd Financial Efficiency Indicators Chart

Kilitch Drugs (India) Ltd Share Holding Pattern

MonthMar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Promoters68.63%68.33%68.33%68.25%68.25%68.25%68.24%68.24%68.24%68.24%69.23%69.23%
FIIs0.00%0.00%0.00%0.03%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public31.37%31.67%31.67%31.73%31.75%31.75%31.75%31.75%31.75%31.76%30.78%30.76%
No. of Shareholders9,7569,2148,7409,1299,1339,2099,3809,4359,5229,5739,0029,062

Kilitch Drugs (India) Ltd Shareholding Pattern Chart

No. of Kilitch Drugs (India) Ltd Shareholders

This stock is not held by any mutual fund

Kilitch Drugs (India) Ltd ROCE Trend

Kilitch Drugs (India) Ltd EPS Trend

Kilitch Drugs (India) Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue10.0010.0010.0010.0010.00
Basic EPS (Rs.)6.714.732.370.552.61
Diluted EPS (Rs.)6.714.732.370.552.61
Cash EPS (Rs.)7.595.573.711.843.83
Book Value[Excl.RevalReserv]/Share (Rs.)96.6490.0383.5678.0580.20
Book Value[Incl.RevalReserv]/Share (Rs.)96.6490.0383.5678.0580.20
Revenue From Operations / Share (Rs.)89.5973.3144.2234.5553.72
PBDIT / Share (Rs.)13.158.525.072.807.17
PBIT / Share (Rs.)10.876.943.791.505.84
PBT / Share (Rs.)7.716.173.301.045.59
Net Profit / Share (Rs.)5.323.992.430.542.49
NP After MI And SOA / Share (Rs.)6.714.732.370.542.49
PBDIT Margin (%)14.6711.6211.478.1013.35
PBIT Margin (%)12.129.468.574.3510.86
PBT Margin (%)8.608.417.473.0110.40
Net Profit Margin (%)5.935.435.491.574.64
NP After MI And SOA Margin (%)7.486.445.351.574.64
Return on Networth / Equity (%)6.895.292.880.713.16
Return on Capital Employeed (%)11.247.694.521.927.25
Return On Assets (%)4.753.511.800.582.66
Total Debt / Equity (X)0.140.140.110.100.07
Asset Turnover Ratio (%)0.650.480.410.380.64
Current Ratio (X)1.841.651.102.543.23
Quick Ratio (X)1.811.571.052.292.99
Inventory Turnover Ratio (X)21.1614.048.317.1014.15
Dividend Payout Ratio (NP) (%)0.000.000.00110.4824.16
Dividend Payout Ratio (CP) (%)0.000.000.0032.7415.73
Earning Retention Ratio (%)0.000.000.00-10.4875.84
Cash Earning Retention Ratio (%)0.000.000.0067.2684.27
Interest Coverage Ratio (X)4.1611.0810.426.0429.06
Interest Coverage Ratio (Post Tax) (X)2.686.185.992.1811.10
Enterprise Value (Cr.)218.65272.89130.24137.43307.18
EV / Net Operating Revenue (X)1.572.391.902.583.72
EV / EBITDA (X)10.6720.5516.5731.8027.88
MarketCap / Net Operating Revenue (X)1.562.291.832.353.68
Retention Ratios (%)0.000.000.00-10.4875.83
Price / BV (X)1.431.880.981.062.51
Price / Net Operating Revenue (X)1.562.291.832.353.68
EarningsYield0.040.020.020.010.01

Kilitch Drugs (India) Ltd Profitability Ratios (%)

Kilitch Drugs (India) Ltd Liquidity Ratios

Kilitch Drugs (India) Ltd Liquidity Ratios (%)

Kilitch Drugs (India) Ltd Interest Coverage Ratios (%)

Kilitch Drugs (India) Ltd Valuation Ratios

Fair Value

Fair Value: ₹249.75

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Overvalued: 25.89% compared to the current price ₹337

Intrinsic Value: ₹440.34

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Undervalued: 30.67% compared to the current price ₹337

Last 5 Year EPS CAGR: 76.31%

*Investments are subject to market risks

Strength and Weakness of Kilitch Drugs (India) Ltd Stock

StrengthWeakness
  1. The company has higher reserves (103.54 cr) compared to borrowings (13.69 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (86.69 cr) and profit (12.62 cr) over the years.
  1. The stock has a low average ROCE of 2.92%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 66.00, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 52.75, which may not be favorable.

FAQ

What is the latest fair value of Kilitch Drugs (India) Ltd?

The latest fair value of Kilitch Drugs (India) Ltd is ₹249.75.

What is the Market Cap of Kilitch Drugs (India) Ltd?

The Market Cap of Kilitch Drugs (India) Ltd is 542 Cr..

What is the current Stock Price of Kilitch Drugs (India) Ltd as on 30 May 2024?

The current stock price of Kilitch Drugs (India) Ltd as on 30 May 2024 is ₹337.

What is the High / Low of Kilitch Drugs (India) Ltd stocks in FY 2024?

In FY 2024, the High / Low of Kilitch Drugs (India) Ltd stocks is 470/175.

What is the Stock P/E of Kilitch Drugs (India) Ltd?

The Stock P/E of Kilitch Drugs (India) Ltd is 43.6.

What is the Book Value of Kilitch Drugs (India) Ltd?

The Book Value of Kilitch Drugs (India) Ltd is 104.

What is the Dividend Yield of Kilitch Drugs (India) Ltd?

The Dividend Yield of Kilitch Drugs (India) Ltd is 0.00 %.

What is the ROCE of Kilitch Drugs (India) Ltd?

The ROCE of Kilitch Drugs (India) Ltd is 9.88 %.

What is the ROE of Kilitch Drugs (India) Ltd?

The ROE of Kilitch Drugs (India) Ltd is 5.40 %.

What is the Face Value of Kilitch Drugs (India) Ltd?

The Face Value of Kilitch Drugs (India) Ltd is 10.0.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Kilitch Drugs (India) Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE